EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

E Eskilsson, GV Røsland, G Solecki, Q Wang… - Neuro …, 2018 - academic.oup.com
Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need
of effective treatment strategies. Recent advances in sequencing techniques unraveled the …

Leptomeningeal metastasis from systemic cancer: review and update on management

N Wang, MS Bertalan, PK Brastianos - Cancer, 2018 - Wiley Online Library
Leptomeningeal metastasis is an uncommon and typically late complication of cancer with a
poor prognosis and limited treatment options. Diagnosis is often challenging, with …

Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity

P Ballard, JWT Yates, Z Yang, DW Kim, JCH Yang… - Clinical Cancer …, 2016 - AACR
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …

[HTML][HTML] Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer

AJ Weickhardt, B Scheier, JM Burke, G Gan… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Many patients with oncogene-driven non–small-cell lung cancer (NSCLC)
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

K Natarajan, Y Xie, MR Baer, DD Ross - Biochemical pharmacology, 2012 - Elsevier
Since cloning of the ATP-binding cassette (ABC) family member breast cancer resistance
protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter …

Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

MC Chamberlain, CS Baik, VK Gadi, S Bhatia… - Neuro …, 2017 - academic.oup.com
Brain metastases (BM) occur frequently in many cancers, particularly non–small cell lung
cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with …

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Y Togashi, K Masago, S Masuda, T Mizuno… - Cancer chemotherapy …, 2012 - Springer
Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

O Bruhn, I Cascorbi - Expert opinion on drug metabolism & …, 2014 - Taylor & Francis
Introduction: Human ATP-binding cassette (ABC) transporters act as translocators of
numerous substrates across extracellular and intracellular membranes, thereby contributing …

Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma

S Agarwal, P Manchanda, MA Vogelbaum… - Drug Metabolism and …, 2013 - ASPET
Despite aggressive treatment with radiation and chemotherapy, recurrence of glioblastoma
multiforme (GBM) is inevitable. The objective of this study was to show that the blood-brain …

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

S Shukla, ZS Chen, SV Ambudkar - Drug resistance updates, 2012 - Elsevier
Tyrosine kinases (TKs) are involved in key signaling events/pathways that regulate cancer
cell proliferation, apoptosis, angiogenesis and metastasis. Deregulated activity of TKs has …